[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,74,114,141,186,215,241,273,295,319,346,377,404,425],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100633441","adapting-cbt-for-pediatric-functional-abdominal-pain-in-primary-care-100633441",false,"NCT07526727","ADAPTing CBT for Pediatric Functional Abdominal Pain in Primary Care","Pilot Testing a Cognitive Behavioral Program Addressing Pediatric Functional Abdominal Pain in Primary Care Settings","ADAPT-PCP","Inclusion Criteria:\n\n* FAPD diagnosis\n* Ages 9-14 years\n* Functional disability score of 7 or greater\n\nExclusion Criteria:\n\n* \\\u003C9 years or \\>14 years\n* Known developmental disability, sensory, or cognitive impairments that limit youths' ability to engage with behavioral programming\n* Unmanaged psychiatric illness (e.g., psychosis, active suicidal ideation, severe depression as indicated in electronic medical records)\n* Symptoms directly attributable to a physical health concern (e.g., cancer, cystic fibrosis, inflammatory bowel disease).\n* Lack of English proficiency","ALL","9 Years","14 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"NA","Many youth experience ongoing stomach pain that does not have a clear medical cause. These conditions, called functional abdominal pain disorders, are common and can last for years. They often interfere with school attendance, daily activities, and social life, and are frequently linked with anxiety. Families may go through many medical tests and appointments without finding relief. The investigator's research shows that teaching these children coping skills, like relaxation, problem solving, and managing anxious thoughts, can reduce pain and improve functioning. The Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a brief program, using cognitive behavioral strategies and mindfulness, the investigators developed that helps children. ADAPT has been shown to work well in specialty clinics, but most children with stomach pain are first seen in primary care, where this type of support is not usually available. The purpose of this project is to test ADAPT in pediatric primary care and test whether it can be delivered successfully. The goal is to improve access to care, reduce symptoms, and better support children.",[27],"Abdominal Pain",[29,30,31,32,33],"functional abdominal pain disorders","pediatrics","cognitive behavioral","mindfulness","primary care","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Michigan State University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100645017","a-pilot-study-using-gut-directed-hypnotherapy-for-hospitalized-patients-100645017","NCT07676136","A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients","Inclusion Criteria:\n\n* Adults admitted to the GI inpatient service with expected length of stay \\>24 hours\n* Prior diagnosis of a disorder of gut-brain interaction, esophageal disorder, or inflammatory bowel disease\n* Reason for hospitalization related to symptom management for exacerbation of visceral pain and\u002For nausea.\n\nExclusion Criteria:\n\n* Currently using hypnosis\n* severe developmental delay or cognitive impairment\n* serious mental illness (i.e. psychosis or dissociation)\n* hearing impairment\n* Non-English speaking\n* enrolled in another trial for GI symptom management\n* admitted for GI procedure","18 Years",{"count":54,"type":21},26,[24],"The purpose of the study is to compare the effectiveness of recorded gut-directed hypnosis to an educational recording in people with chronic problems in their gastrointestinal (GI) system. Patients who are hospitalized at Stanford Hospital for worsening pain and\u002For nausea will be considered for enrollment.",[58,59,60,27,61],"Disorders of Gut-brain Interaction","Inflammatory Bowel Disease (IBD)","Irritable Bowel Syndrome","Esophageal Disease",[63],"hypnosis","2026-06-23",{"date":66,"type":38},"2026-06-30",{"date":68,"type":21},"2026-07",{"date":70,"type":21},"2028-07",{"name":72,"class":45},"Stanford University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":98,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":73},"100557838","marginal-ulcer-healing-with-low-thermal-argon-plasma-endoscopic-treatment-100557838","NCT06543316","Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","Accelerated Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","AMULET","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.\n* Subjects must be scheduled for an EGD for the evaluation of these symptoms.\n* Marginal ulcers confirmed during the initial EGD.\n* Willingness to adhere to the SOC treatment, which includes PPIs.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent and understanding of study requirements.\n* Willingness and ability to attend required follow-up assessments at 4 weeks (+\u002F- 1 week) and 8 weeks (+\u002F- 2 weeks).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Inability or unwillingness to comply with the SOC.\n* Current use of systemic antibiotics.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.",{"count":83,"type":21},100,[24],"The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.",[87,88,89,90,91,92,27,93,94,95,96,97],"Roux-en-y Anastomosis Site","Marginal Ulcer","Marginal Ulcer (Peptic) or Erosion","Ulcer","Ulcer, Gastric","Ulcer Gastrointestinal","Nausea","Vomiting","GastroIntestinal Bleeding","Dysphagia","Ulcer Gastrojejunal",[99,100,101,102,103,104,105],"Argon Plasma Coagulation","APC","Low-Thermal Argon Plasma Endoscopic Treatment","Endoscopy","RYGB","Roux-en-Y Gastric Bypass","Ulcer Healing","RECRUITING",{"date":35,"type":38},{"date":109,"type":38},"2025-03-04",{"date":111,"type":21},"2028-06",{"name":113,"class":45},"Christopher C. Thompson, MD, MSc",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":73},"100641990","navicam-patency-capsule-to-verify-gastrointestinal-patency-100641990","NCT07649720","NaviCam Patency Capsule to Verify Gastrointestinal Patency","A Prospective, Single Center Clinical Trial Assessing the Efficacy and Safety of the NaviCam Patency Capsule to Verify Gastrointestinal Patency","PATENCY","Inclusion Criteria:\n\n* Patients with suspected or known intestinal stricture (with medical history records, physical examination records, and imaging evidence within the last 6 months.\n* Patients suffering from Crohn's Disease\n* Patients with long-term use of non-steroidal anti-inflammatory drugs.\n* Patients with abdominal symptoms related to intestinal stricture.\n* Patients with chronic inflammatory diseases.\n* Patients with difficulty with balloon-assisted endoscopy (BAE).\n* Patients with a history of small bowel obstruction.\n* Patients with a history of intestinal resection surgery.\n\nExclusion Criteria:\n\n* Patients with esophageal obstruction or swallowing disorder diseases.\n* Patients who are ineligible for surgery or refuse to undergo any abdominal surgery.\n* Patients with known allergies or other contraindications or intolerance to the medications used in this study.\n* Patients with pacemakers or other implanted electronic devices such as cochlear implants, magnetic metal drug infusion pumps, neurostimulators.\n* Pregnant women\n* Patients currently enrolled in another drug or device clinical trial.\n* Other conditions deemed unsuitable for inclusion by the investigator.","22 Years",{"count":124,"type":21},25,[24],"Participants included in this study will first swallow a patency capsule and then undergo an abdominal X-ray scan within 30 hours after swallowing the capsule to confirm weather the capsule is still in the body.",[128,129,130,27],"Intestinal Stricture","Crohn Disease","NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy","2026-06-10",{"date":133,"type":38},"2026-06-16",{"date":135,"type":21},"2026-06-15",{"date":137,"type":21},"2027-03-15",{"name":139,"class":140},"AnX Robotica Corp.","INDUSTRY",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":155,"conditions":156,"keywords":160,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100580300","phase-3-morphine-or-ketamine-for-analgesia-100580300","NCT06835504","Morphine or Ketamine for Analgesia","Efficacy of Intravenous Sub-Dissociative Ketamine Versus Intravenous Morphine in Children With Acute Pain","MoKA","Inclusion Criteria:\n\n1. Abdominal pain or isolated long-bone extremity fracture (suspected or proven)\n2. Self-reported pain score of ≥ 6\u002F10\n3. Requires IV morphine for analgesia as determined by the treating physician\n\nExclusion Criteria:\n\n1. Weight \\> 82.4 kg\n2. Known allergy\u002Fcontraindication to morphine or ketamine\n3. Antecedent receipt of ketamine related to presenting complaint\n4. Inability to use self-report measures of pain or questionnaires\n5. Chronic disease associated with pain\n6. Chronic pain condition requiring use of opioids as outpatient\n7. Hemodynamic instability or critical illness per treating physician\n8. Altered mental state (e.g., GCS , 14 or clinical intoxication)\n9. Known history of schizophrenia, liver or kidney problems, or osteogenesis imperfecta\n10. Concern for open fracture, neurovascular compromise, or compartment syndrome\n11. Injuries in addition to the extremity injury (e.g., head, neck, abdomen)\n12. Known or reported pregnancy\n13. Does not speak English or Spanish\n14. Patient previously enrolled in this study\n15. Wards of state, foster children, or children in custody","6 Years","17 Years",{"count":152,"type":21},1010,[154],"PHASE3","Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use\u002Fmisuse, and mental and behavioral health outcomes.",[27,157,158,159],"Isolated Extremity Fracture","Pain","Pediatrics",[161,162,163,164,165,166,167,168,169,170,171,172,173,174,175],"Ketamine","Morphine","Pediatric","Children","Sub-dissociative","Opioid-sparing","Emergency medicine","Emergency care","Emergency department","Post-traumatic stress","Anxiety","Depression","Abdominal pain","Fracture","Analgesia","2026-06-08",{"date":178,"type":38},"2026-06-09",{"date":180,"type":21},"2026-09-01",{"date":182,"type":21},"2030-02-28",{"name":184,"class":45},"Columbia University",8,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":73},"100640341","a-study-evaluating-the-impact-of-regular-fodmap-targeting-digestive-enzyme-blend-use-on-gastrointestinal-symptoms-in-individuals-with-self-reported-bloating-100640341","NCT07591584","A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating","Inclusion Criteria:\n\n* Individuals aged 18 years old or older\n* Screening score of \\>= 55 on the PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a scale.\n* Screening severity score of \\>= 55 on the PROMIS Scale v1.0 - Gastrointestinal Belly Pain scale.\n* Screening score of \\\u003C10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n* Adults with or without IBS are eligible; participants with IBS experiencing symptoms must meet the Rome IV criteria as determined by the Rome IV Diagnostic Questionnaire (R4DQ) IBS Module.\n* Able to maintain 80% compliance with daily questionnaires during the 2 week run-in period.\n* In good general health at the time of screening (Investigator discretion).\n* Able to read and understand English and provide informed consent.\n* Able to use a personal smartphone device and download Chloe by People Science.\n* Able to receive shipment of the product at an address within the United States.\n* Able to complete study assessments over the course of up to 19 weeks.\n\nExclusion Criteria:\n\n* Do not have a personal smartphone, internet access, or unwilling to download Chloe.\n* Concomitant Therapies:\n\nParticipants receiving any of the following treatments or therapies are excluded:\n\n* Any investigational therapies or treatments (pharmaceuticals, devices, supplements) within 30 days prior to randomization.\n* Ongoing psychological therapies specifically targeting gastrointestinal symptoms or functional disorders, including but not limited to GI-directed Cognitive Behavioral Therapy (CBT), GI hypnotherapy, or other therapies for Disorders of Gut-Brain Interaction (DGBI).\n* Treatment with Glucagon-like peptide-1 (GLP-1) agonists (e.g., semaglutide, tirzepatide) within the last 90 days prior to randomization, due to their known effects on gut motility and GI symptoms.\n* Current or recent (within the last 6 months) chemotherapy or immunotherapy for cancer treatment.\n* Current or planned use of any other digestive enzymes prescription or over-the-counter (OTC).\n* Chronic use (defined as daily use for \\>30 days within the last 90 days) of any medication known to have substantial gastrointestinal side effects (e.g., diarrhea, constipation, nausea) that, in the opinion of the Principal Investigator, may confound the assessment of study outcomes. This may include high-dose NSAIDs, opioids, prokinetics, bile acid binders, or certain antibiotics.\n* Variable use of probiotics, fiber supplements, laxatives, stool softeners, antidiarrheals (if taking) in the last 30 days. Variable use is defined as use of any probiotic, fiber supplement, laxative, stool softener, or antidiarrheal with a dose change greater than 50% in the last 30 days or initiation or discontinuation of a gut-active product in the last 30 days.\n\n  * Other Illnesses or Conditions:\n\nParticipants who have the following comorbidities or gastrointestinal illnesses are excluded:\n\n* Currently diagnosed with Alcohol Use Disorder and\u002For Substance Use Disorder\n* Currently pregnant, planning to become pregnant in the next 4 months, or breastfeeding\n* History of bariatric or other significant gastrointestinal surgery (e.g., small bowel resection, total colectomy) that has permanently altered GI anatomy or function. Standard appendectomy or cholecystectomy are generally permitted.\n\nAny underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes (e.g., Type I diabetes, Endometriosis, etc.).\n\n* Acute gastroenteritis within the past 4 weeks;\n* New diagnosis workup planned during study that may change diagnosis\u002F behavior\u002F medications (eg. colonoscopy prep or major bowel cleanse, upcoming GI consult that could affect eligibility).\n* Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.\n\n  * Self-reported known hypersensitivity or previous allergic reaction to corn and\u002For any previous reaction to digestive enzyme supplements (eg. Beano and Lactaid)\n  * Comorbid GI conditions: IBD - Ulcerative Colitis or Crohn's Disease, Microscopic Colitis, history of small bowel or colonic surgeries, Celiac disease, or Bile Acid Malabsorption (BAM).\n  * Screening score of ≥10 on the Generalized Anxiety Disorder 7-item (GAD-7) scale\n  * On a low FODMAP diet based on FODMAP FFQ results at Screening\n  * History of following a low FODMAP diet in the past 6 months (self-reported)\n  * Any history of following LFD (Low FODMAP Diet) with no response (i.e. failed LFD in past)\n  * Participants who are on or plan to initiate a major restrictive or elimination diet, or a structured weight-loss diet, during the study period.\n  * No planned changes in diet, lifestyle or medications for IBS during study period.\n  * Use of any antibiotics, antifungals, or antivirals within 2 weeks prior to randomization.\n  * Participants planning extended travel that would interfere with compliance or study procedures.\n  * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.",true,{"count":194,"type":21},150,[24],"This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on gastrointestinal symptoms in adults with self-reported bloating.1\n\nThe study's rationale is based on the fact that fermentable carbohydrates (FODMAPs) are often poorly absorbed and can trigger symptoms like bloating and abdominal pain. While a Low FODMAP Diet (LFD) is clinically validated for symptom relief, it is restrictive. The enzyme blend is intended to offer a more flexible, enzyme-based solution by targeting and breaking down FODMAPs, such as fructan, GOS, and lactose, before they ferment in the colon.\n\nThe primary objective is to evaluate the product's impact on bloating symptoms, measured by the mean PROMIS scale Gastrointestinal Gas and Bloating score. Secondary and exploratory objectives include assessing the impact on overall gastrointestinal symptom severity (IBS-SSS), abdominal pain (PROMIS Belly Pain score), food-related quality of life (FR-QoL-29), and anxiety (GAD-7 scores). The study also aims to evaluate these effects across various Irritable Bowel Syndrome (IBS) subgroups (IBS-C, IBS-D, IBS-M). The trial is a consumer-driven, decentralized research study utilizing validated patient-reported outcome measures that can be completed in a home setting.",[198,199,27,200],"IBS (Irritable Bowel Syndrome)","Bloating","Gut Health",[202,203,204,205],"bloating","gas","abdominal pain","IBS","2026-05-11",{"date":208,"type":38},"2026-05-15",{"date":210,"type":38},"2026-05-04",{"date":212,"type":21},"2026-10-26",{"name":214,"class":140},"Kiwi Health Inc",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":73},"100579702","pocus-impact-on-the-diagnostic-approach-for-thoracic-and-abdominal-pain-in-the-ed-100579702","NCT06827730","PoCUS Impact on the Diagnostic Approach for Thoracic and Abdominal Pain in the ED","DATAPUS","Inclusion Criteria:\n\n* \\> 17 years\n* Thoracic or abdominal pain for less than 72 hours\n* Signed informed consent\n\nExclusion Criteria:\n\n* Reasons making abdominal ultrasound impossible\n* Discovery of a pregnancy during emergency care\n* Follow-up impossible at one month",{"count":223,"type":21},406,[24],"Many medical specialties and paramedical fields are increasingly using point-of-care ultrasound (PoCUS). In daily practice, thoracic and abdominal pain constitute a significant portion of emergency department consultations. PoCUS can be employed in various ways during thoracic and abdominal physical examinations. Most scientific societies advocate for its use to address specific clinical questions rather than to provide a definitive diagnosis.\n\nThe integration of PoCUS into clinical examinations raises the question of its effectiveness in improving the diagnostic approach, rather than its diagnostic accuracy alone. Given the broad spectrum of differential diagnoses for thoracic and abdominal pain, this multicenter prospective study protocol aims to evaluate how PoCUS enhances the diagnostic approach for patients presenting with these symptoms in the emergency department.\n\nTo assess the contribution of PoCUS, three members of an adjudication committee will blindly choose between two case report forms reporting the planned diagnostic approach for each patient: one completed before PoCUS and the other after its use by the investigator handling the case. The hypothesis that PoCUS improves the diagnostic approach by 60% will be reached if 60% of the improved diagnostic approaches favor the case report form filled out after PoCUS.",[27,227],"Thoracic Pain",[229,204,230,231],"thoracic pain","point of care ultrasound","diagnostic approach","2026-04-24",{"date":234,"type":38},"2026-04-30",{"date":236,"type":38},"2025-06-01",{"date":238,"type":21},"2029-06-01",{"name":240,"class":45},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":73},"100495384","online-social-learning-program-for-parents-with-irritable-bowel-syndrome-raising-resilient-children-100495384","NCT05730491","Online Social Learning Program for Parents With Irritable Bowel Syndrome: Raising Resilient Children","Randomized Controlled Trial of an Internet-based Prevention Intervention for Parents With Irritable Bowel Syndrome","REACH","Inclusion criteria for parents and their children (including biological\u002Fstep-parents or legal guardians):\n\n* Parent\u002Fcaregiver at least 18 years old\n* Parent diagnosed with IBS or idiopathic abdominal pain in the last five years OR\n* Parent meets ROME criteria for IBS (abdominal pain at least weekly; pain related to defecation, change in stool frequency, and change in stool form at least 30% of the time)\n* Is the parent primarily responsible for caring for the child on a day-to-day basis\n* Child is 4 to 7 years old at the time of screening. If multiple children are present in the family, the parent will be asked to select one child for study participation.\n* Child must currently live at least half of the time with the parent involved in intervention.\n* Parent and child must reside in the U.S.\n\nExclusion criteria for parents and their children:\n\n* Not able to read\u002Fspeak\u002Funderstand English.\n* Child has a developmental disability that requires full-time special education\n* Child has chronic abdominal pain (pain most\u002Fevery day for more than 3 months)\n* Child has a current doctor's diagnosis of a painful\\* gastrointestinal disorder like functional constipation, lactose\u002Ffructose\u002Fgluten intolerance, celiac disease, Inflammatory Bowel Disorder, etc. (\\*does not include nonpainful disorders like GERD)\n* Child has another severe chronic disease such as juvenile arthritis, cancer, or other severe condition(s) requiring chronic medical treatment.\n* Does not have regular access to the Internet on a desktop, tablet, phone, or laptop computer",{"count":250,"type":21},460,[24],"The goal of this clinical trial is to test efficacy of the REACH program in parents with irritable bowel syndrome (IBS) and their young children. The main question it aims to answer is:\n\n-How can parents with IBS help their young kids develop healthy habits?\n\nParticipants will be asked to complete online surveys and to use a website. Researchers will compare results from parents who use one of two websites chosen by chance, like flipping a coin. One website focuses on child health and safety behaviors. The other website focuses on strategies to promote child wellness behaviors.",[60,27],[255,256,257,258,259,260,261,204,262,263],"social learning","cognitive behavioral therapy","prevention intervention","irritable bowel syndrome","solicitous behavior","protective factors","psychosocial intervention","risk factors","illness behavior","2026-02-12",{"date":266,"type":38},"2026-02-17",{"date":268,"type":38},"2023-10-16",{"date":270,"type":21},"2027-04-30",{"name":272,"class":45},"Seattle Children's Hospital",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":280,"maxAge":52,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":73},"100526393","safety-and-efficacy-of-carbon-dioxide-gas-for-endoscopy-100526393","NCT06134154","Safety and Efficacy of Carbon Dioxide Gas for Endoscopy","Safety and Efficacy of Carbon Dioxide Gas for Endoscopic Insufflation in Children","Inclusion Criteria:\n\n\\- Infants and children 6 months to 18 years undergoing any upper endoscopy related procedure including but not limited to EGD\u002FColonoscopy, ERCP, EGD only, EUS, EGD with foreign body removal, Enteroscopy.\n\nExclusion Criteria:\n\n* Patients with American Society of Anesthesiology (ASA) Physical Status Classification System of 4 and above\n* Children with chronic lung disease,\n* Children who are wards of the state will be excluded.\n* Children needing language interpreting services that is not Spanish.","6 Months",{"count":282,"type":21},350,[24],"The goal of this clinical trial is to compare the efficacy and safety of air versus carbon dioxide gas insufflation for endoscopy in children.\n\nThe main question\\[s\\] it aims to answer are:\n\n•to determine safety of CO2 Assess patient comfort (abdominal pain, flatulence and bloating) with CO2 use when compared to air.",[27],"2026-01-21",{"date":288,"type":38},"2026-01-23",{"date":290,"type":38},"2024-01-24",{"date":292,"type":21},"2028-12",{"name":294,"class":45},"University of Alabama at Birmingham",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":304,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":73},"100618978","the-auxiliary-effect-of-artificial-intelligence-in-the-detection-of-precancerous-lesions-in-proximal-colon-cancer-100618978","NCT07338643","The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer","The Auxiliary Effect of Artificial Intelligence in the Detection of Precancerous Lesions in Proximal Colon Cancer: A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1.Patients with symptoms such as abdominal pain, black stools, constipation, or diarrhea undergo colonoscopy for diagnostic purposes.\n\nExclusion Criteria:\n\n1. Those with inflammatory bowel disease, colorectal cancer and surgical history, as well as those with familial polyposis syndrome\n2. Those with intestinal obstruction or malignant tumors\n3. Patients with colorectal lesions that need to be treated in stages.\n4. Other contraindications for colonoscopy examination.",{"count":303,"type":21},1200,"OBSERVATIONAL","The investigators conducted a multicenter randomized controlled trial to explore the adjuvant effect of artificial intelligence in the detection of precancerous lesions in the proximal colon.This is a prospective, multicenter, single-blind, parallel randomized controlled trial.During the colonoscopy retraction process, the investigators aimed to compare the detection rates of proximal colon adenomas with and without the assistance of an AI(Artificial Intelligence) diagnostic device.",[27,307,308,309],"Black Stools","Constipation","Diarrhea","2026-01-03",{"date":312,"type":38},"2026-01-14",{"date":314,"type":21},"2026-02-26",{"date":316,"type":21},"2028-08-01",{"name":318,"class":45},"Limian Er",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":192,"sex":17,"minAge":52,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":73},"100545439","objective-integrated-multimodal-electrophysiological-index-for-the-quantification-of-visceral-pain-100545439","NCT06381921","Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain","OIME - Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain","OIME","Inclusion Criteria:\n\n* Participants need to be diagnosed with IBS by a healthcare provider according to Rome-III or -IV criteria, with a current report of abdominal pain.\n* Men and women 18-50 years old\n* Able to read and speak English\n* Daily access to a computer with internet access.\n\nExclusion Criteria:\n\n* Other chronic pains that are usually not comorbid with IBS, e.g., diabetic neuropathy, myofascial pain, low back pain, peripheral neuropathy etc.\n* Celiac disease or inflammatory bowel disease\n* Diabetes mellitus; d) Serious mental health conditions\n* Women during pregnancy or within 3 months post-partum period\n* Self- reported Regular use of opioids or other illicit substances.\n* Participants who have had COVID-19 should be fully recovered, and will be asked if their medical provider has made any restriction on activities.","50 Years",{"count":329,"type":21},120,[24],"The objectives of the study are to 1) Conduct telemetric biosignals (EDA, ECG, and EMG) recording in healthy controls and IBS participants experiencing cutaneous and visceral pain; and 2) Validate the OIME index as a biomarker for quantifying pain in IBS participants and its capability to assess the treatment of IBS pain via an ambulatory trial.",[27],[334,258,335,336,337],"visceral pain","autonomic and muscular activities","biosignals","personalized pain self-management","2025-09-08",{"date":340,"type":38},"2025-09-15",{"date":338,"type":38},{"date":343,"type":21},"2029-02-28",{"name":345,"class":45},"University of Connecticut",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":192,"sex":353,"minAge":52,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":73},"100604868","different-intraperitoneal-pressures-on-optic-nerve-sheath-diameter-in-laparoscopic-surgeries-100604868","NCT07155109","Different Intraperitoneal Pressures on Optic Nerve Sheath Diameter in Laparoscopic Surgeries","The Effects of Different Intraperitoneal Pressures on Optic Nerve Sheath Diameter in Laparoscopic Gyneco-oncologic Surgeries","Inclusion Criteria:\n\n* Laparoscopic gyneco-oncological surgeries\n* Female patients aged 18-65 years\n* ASA physical status classification I-II-III patients\n\nExclusion Criteria:\n\n* Patients with diabetic retinopathy\n* Patients with glaucoma\n* Patients with cerebrovascular disease\n* Pregnant women\n* Patients with known allergy to anaesthetic agents\n* Morbidly obese patients with BMI \\> 40","FEMALE","65 Years",{"count":83,"type":21},[24],"The aim of this study is to investigate the effects of low and normal intraperitoneal pressures on intraoperative optic nerve sheath diameter in laparoscopic gyneco-oncologic surgeries.",[359,27,360],"Intracranial Pressure Increase","Head Pain",[362,363,364,365,366],"Intracranial Pressure","optic nerve","laparascopy","gyneco-oncologic surgery","low pressure","2025-08-27",{"date":369,"type":38},"2025-09-04",{"date":371,"type":21},"2025-08-30",{"date":373,"type":21},"2025-10-20",{"name":375,"class":376},"Diskapi Yildirim Beyazit Education and Research Hospital","OTHER_GOV",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":73},"100528438","phase-3-intravenous-ketorolac-vs-morphine-in-children-with-acute-abdominal-pain-100528438","NCT06160778","Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain","Intravenous Ketorolac Vs. Morphine In Children Presenting With Acute Abdominal Pain And\u002For Suspected Appendicitis: A Multi-centre Non-Inferiority Randomized Controlled Trial","KETOAPP","Inclusion Criteria:\n\n1. Age 6 to 17 years\n2. Abdominal pain ≤5 days duration\n3. Acute abdominal pain that is being investigated (suspected) by the clinical team for appendicitis\n4. Patient with IV cannula in situ or ordered\n5. Currently experiencing moderate to severe abdominal pain at rest or with movement: self-reported pain score ≥5 using the verbal Numerical Rating Scale\n\nExclusion Criteria:\n\n1. Previous enrollment in the trial\n2. NSAID use within 3 hours and\u002For opioid use within 1 to 2 hours (1 hour post-IV or intra-nasal fentanyl and 2 hours post IV morphine).\n3. Children who need immediate resuscitation, are hemodynamically unstable as deemed by the clinical team or have a Canadian Triage Assessment Score of 1\n4. Significant caregiver and\u002For child cognitive impairment precluding the ability to complete study questions.\n5. Chronic pain requiring daily analgesic use: confounding as response to analgesics maybe altered.\n6. History of severe undiagnosed gastrointestinal bleeding requiring medical intervention, peptic or duodenal ulcer disease or inflammatory bowel disease, coagulation disorders, prior cerebrovascular bleeding, known arterio-vascular malformations. History of minor gastrointestinal bleeding from conditions such as resolved fissures, polyps or allergic colitis will not exclude patients from participating.\n7. History of chronic and active interstitial kidney disease\n8. History of chronic and active hepatocellular disease: ketorolac is metabolized by the liver.\n9. Known or suspected pregnancy at the time of enrollment or breastfeeding females\n10. Known hypersensitivity to NSAIDs or opioids.\n11. Absence of a parent\u002Fguardian for children who are \\\u003C16 years of age if they are not a mature minor.\n12. Inability to obtain consent due to a language barrier and the absence of language translator in person or by a phone translation service available in the ED.",{"count":386,"type":21},495,[154],"Appendicitis is a common condition in children 6-17 years of age, and the top reason for emergency surgery in Canada. Children with appendicitis can have very bad pain in their belly. Children often need pain medications given to them through a needle in their arm called an intravenous (IV). The most common IV pain medication is a type of opioid called morphine. We know that opioids work well to improve pain, but there are risks and side effects when taking them. There are non-opioid medications that doctors can give to patients, like ketorolac. Ketorolac helps decrease inflammation and pain and has fewer side effects when a patient takes it for a short period of time. Our past and present overuse of opioids, driven by an unproven assumption that opioids work best for pain, resulted in an Opioid Crisis and doctors are now looking for alternatives. To do this, we need to prove that there are other options to treat children's pain that are just as good as opioids, with less side effects.\n\nThe goal of our study is to discover if school aged children who arrive at the emergency department with belly pain, improve just as much with ketorolac as they do with morphine. To answer this question, we will need a very large number of patients in a study that includes several hospitals across Canada. With a flip of a coin, each participant will either get a single dose of morphine or a single dose of ketorolac. To make sure that our pain assessment is impartial, no one will know which medicine the child received except the pharmacist who prepared the medicine.",[390,391,27,392,393,394],"Acute Pain","Abdomen, Acute","Appendicitis","Emergencies","Child, Only","2024-06-21",{"date":397,"type":38},"2024-06-24",{"date":399,"type":38},"2024-05-27",{"date":401,"type":21},"2029-12",{"name":403,"class":45},"University of Calgary",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":192,"sex":17,"minAge":52,"maxAge":411,"enrollmentInfo":412,"targetDuration":4,"studyType":304,"phases":4,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100530977","diagnostic-laparoscopy-for-unexplained-abdominal-pain-100530977","NCT06193798","Diagnostic Laparoscopy for Unexplained Abdominal Pain","Diagnostic Laparoscopy For Unexplained Abdominal Pain Risks &Benefits","Inclusion Criteria:\n\n* Patients with obscure abdominal pain\n* Age from 18 years old up to 70 years old\n\nExclusion Criteria:\n\n1. Current use of narcotics\n2. patients have uncontrolled coagulopathy\n3. Patients are Haemodynamically unstable\n4. patients have Cardiopulmonary problems\n5. Patients refusing the diagnostic laparoscopy after routine investigations","70 Years",{"count":413,"type":21},20,"To evalute the efficiency and safety of diagnostic laparoscopy for patients who have unexplained abdominal pain after completing all needed imaging and laboratories in general surgery depatment Assuit university hospital",[27],"2024-01-19",{"date":418,"type":38},"2024-01-22",{"date":420,"type":21},"2024-03-20",{"date":422,"type":21},"2026-11-11",{"name":424,"class":45},"Assiut University",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":411,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":444,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":4},"100516284","relief-pathway-in-patients-with-upper-abdominal-pain-100516284","NCT06002516","RELIEF-pathway in Patients With Upper Abdominal Pain","The RELIEF-pathway in Patients With Upper Abdominal Pain; an Open-label Multicenter Randomized Controlled Trial","RELIEF","Inclusion Criteria:\n\n* Patients between 18 and 70 years old.\n* First referral due to upper abdominal pain (UAP) and symptoms due to Functional dyspepsia (ICPC code 87.02), Irritable Bowel syndrome (ICPC 93.0) or uncomplicated symptomatic cholecystolithiasis (ICPC 98.03).\n* Proficient in reading and understanding of the Dutch language.\n* Referred to the outpatient clinic of gastroenterology or surgery.\n* Providing informed consent.\n\nExclusion Criteria:\n\n* If the following alarm symptoms are reported in the referral letter by the GP: weight loss, persistent vomiting, dysphagia, jaundice, hematemesis, melena, haematochezia, or anaemia.\n* Any other direct or indirect signs of cancer or upper GI tract bleeding.\n* Patients with a first or second-degree relative with a history of upper GI tract malignant neoplasm.\n* Patients with a history of complicated cholecystolithiasis.\n* A history of or current malignancy (except SCC or BCC of the skin).\n* Pregnancy;\n* Expected short life span of less than 12 months.\n* Known cirrhosis of the liver\n* Current schizophrenia, memory deficiency, or any other disorder that predispose them to unreliable questionnaire responses;\n* Mentally incompetent;",{"count":434,"type":21},471,[24],"Upper abdominal pain (UAP) is a common symptom and frequently the reason to visit the hospital. The prevalence of epigastric pain in the Dutch population is estimated to be as high as 37%. Moreover, Dutch hospitals yearly record \\>100.000 diagnoses related to UAP. In most patients, UAP can be attributed to symptomatic (functional) dyspepsia (FD), Irritable Bowel Syndrome (IBS) or uncomplicated gallstone disease (cholecystolithiasis), with a prevalence in the general population of 20-30%, 20%, and 6-9%, respectively. However, these conditions may have overlapping symptom patterns and generally affect similar populations. which contributes to ineffective (diagnostic) interventions. Patients are generally not aware of the similarity of symptoms and the poor outcome of some treatments.\n\nEducation positively influences patients' self-management and health judgment. In a recent open-label, multicentre trial the effectiveness of web-based patients' education is applied to reduce overuse of upper gastrointestinal endoscopies in patients with dyspepsia. This study illustrated that an web-based education tool safely reduced 40% in upper gastrointestinal endoscopies. Lifestyle interventions (such as change of diet and\u002For physical activity) are widely incorporated in treatment programs for cardio-vascular diseases including diabetes mellitus and obesity. An web-based education tool on upper abdominal pain and other complaints combined with a lifestyle interventions for patients may be an effective treatment option for this large group of patients.\n\nThis study investigates the potential of an individualized web-based education tool as intervention for patients with functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis with the possibility to visit the Prevention and Lifestyle clinic (RELIEF pathway). The RELIEF pathway aims to reduce unnecessary health care utilization and, secondly, to maintain and improve quality of life by educating patients on lifestyle improvement.",[27,438,439,60,440,441,442,443],"Gallstone; Colic","Dyspepsia","Health Care Utilization","Patient Reported Outcomes","Upper Abdominal Pain","Decision Aid",[173,445],"Health care utilization","2023-08-15",{"date":448,"type":38},"2023-08-21",{"date":450,"type":21},"2024-05-01",{"date":452,"type":21},"2027-05-01",{"name":454,"class":45},"Radboud University Medical Center"]